Balancing the outcomes: reporting adverse events

• 1 NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW.
• 2 Department of Physiology, University of Sydney, Sydney, NSW.

---

• 1. Altman DG, Schulz KF, Moher D, et al, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663–694.
• 2. Note for guidance on good clinical practice (CPMP/ICH/135/95): annotated with TGA comments. Canberra: Therapeutic Goods Administration, Department of Health and Aged Care, 2000. Available at: www.tga.gov.au/docs/html/ich13595.htm (accessed Jul 2004).
• 3. Note for guidance on clinical safety data management: definitions and standards for expedited reporting (CPMP/ICH/377/95). Annotated with TGA comments. Canberra: Therapeutic Goods Administration, Department of Health and Aged Care, 2000. Available at: www.tga.gov.au/docs/html/ich37795.htm (accessed Jul 2004).
• 4. International statistical classification of diseases and related health problems, tenth revision. Geneva: World Health Organization; 1992.
• 5. International Conference on Harmonization. Medical dictionary for regulatory activities (MedDRA). Available at: www.meddramsso.com/NewWeb2003/medra_overview/index.htm (accessed Jun 2004).
• 6. Common terminology criteria for adverse events v3.0 (CTCAE). Bethesda, Md.: National Cancer Institute Cancer Therapy Evaluation Program, 2003. Available at: http://ctep.cancer.gov/reporting/ctc.html (accessed Mar 2004).
• 7. Note for guidance on good clinical practice (CPMP/ICH/135/95). European Agency for the Evaluation of Medicinal Products, 2002. Available at: www.emea.eu.int/pdfs/human/ich/013595en.pdf (accessed Jul 2004).
• 8. Liauw WS, Day RO. Adverse event reporting in clinical trials: room for improvement. Med J Aust 2003; 179: 427-428.
• 9. Draft guidance for clinical trial sponsors on the establishment and operation of clinical trial monitoring committees. Food and Drug Administration, 2001. Available at: www.fda.gov/cber/gdlns/clindatmon.htm (accessed Jul 2004).
• 10. Toner GC, Stockler MR, Boyer MJ, et al, for the Australian and New Zealand Germ Cell Trial Group. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Lancet 2001; 357: 739-745.
• 11. Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med 2004; 350: 2452-2460.
• 12. National statement on ethical conduct of research involving humans. Part 12 — clinical trials. Canberra: National Health and Medical Research Council, 2003. Available at: www.nhmrc.gov.au/publications/humans/part12.htm (accessed Jul 2004).
• 13. Edwards JE, McQuay HJ, Moore A, Collins SL. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage 1999; 18; 427-437.
• 14. Jarensiripornkul N, Krska J, Capps PAG, et al. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002; 53: 318-325.
• 15. Curb JD, Borhani NO, Blaszkowski TP, et al. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA 1985; 253: 3263-3268.
• 16. Heritier SR, Gebski VJ, Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust 2003; 179: 438-440. <eMJA full text>
• 17. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001; 1: 7.
• 18. Parving HH, Lehnert H, Broechner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 345: 870-878.
• 19. Perrone F, De Maio E, Maione P, et al. Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer. J Clin Oncol 2001; 20: 52-57.
• 20. Ioannidis J, Contopoulois-Ioannidis D. Reporting of safety data from randomised trials. Lancet 1998; 352: 1752-1753.
• 21. Ioannidis J, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-443.
• 22. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials — a systematic survey. BMC Clin Pharmacol 2001; 1: 3.
• 23. Trotti A, Benzten SM. The need for adverse event reporting standards in oncology clinical trials. J Clin Oncol 2004; 22: 19-22.
• 24. Mills E, Loke YK, Wu P, et al. Determining the reporting quality of RCTs in clinical pharmacology. Br J Clin Pharmacol 2004; 58: 61-65.
• 25. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomised trials: comparison of protocols to published articles. JAMA 2004; 291: 2457-2465.
• 26. Mucklow JC. Reporting drug safety in clinical trials: getting the emphasis right [letter]. Lancet 2001; 357: 1384.
• 27. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004; 57: 616-621.